Stock name 2-day closing price ⇒ previous day comparison.

Next Stage <3186> 2200 -214

There is a reduced profit for the 3-5 month operating profit.

Insource <6200> 795 -51

Due to the continued rise in interest rates, it is relatively difficult to buy growth stocks.

Tsuburaya Fields Holdings <2767> 1680 -37

The supply and demand factors due to the decline in growth stocks may have an impact.

Kadokawa <9468> 2613.5 -64.5

Continued vigilance against damage from server attacks.

Shift <3697> 14075 -320

Morgan Stanley MUFG Securities lowers its target stock price.

Peptide Dream <4587> 2327.5 -95.5

Short-term profit-taking selling is dominant due to the feeling of reaching the upper limit.

SocioNext <6526> 3780 -69

Semiconductor related stocks are generally sluggish on the 2nd day.

M&A Research HD <9552> 3855 -60

Sell-offs are dominant since the rebound peak last weekend.

Sumitomo Pharma <4506> 378 -12

Returning selling pressure since Day 1 due to the end of the rebound.

Atlae <6194> 767 -10

There is also a feeling of a downturn in the evaluation of increased dividends.

Kamakura Shinsho <6184> 410 -6

Due to the trend of cutting losses with stocks below their price floors.

Mitsubishi UFJ <8306> 1811 +62

Financial stocks are high due to the rise in long-term interest rates in Japan and the US.

Via HD <7918> 132 +11

There is no particular material, so we expect the rebound to continue.

GMO-AP <4784> 603 -144

Profit-taking sales due to overheating alertness are dominant.

Tasuki HD <166A> 624 +11

Acquired a patent for an AI service for generating building plans and started external provision.

Linkers <5131> 214 -5

Fukui Bank <8362> introduces a business matching system for financial institutions.

It temporarily became popular, but has a long upper shadow.

AHC Group <7083> 2480 -345

Achievement feeling on June 27th high. Continued selling to close out positions.

LaboroAI<5586> 1403 +149

On the 1st, the upward trend above the 25-day moving average is gaining momentum.

Cellseed<7776> 385 -49

Continues to provide clues such as US patent examination of cartilage cell sheets.

Helios<4593> 174 -11

Dislike the change in the deadline for the expected partnership contract with Nobel Pharma.

Ligua<7090> 2390 +400

On the 1st, the stock price hit the daily limit two days in a row. On the 2nd, it continued to rise after absorbing profit-taking sells.

Neuroimmunology<4893> 228 +8

Announcing the re-prioritization of its in-house drug pipeline, temporarily gaining popularity on the 1st, but with a long upper shadow. On the 2nd, buying was dominant once again.

Perseus<4882> 461 -58

On the 1st, the stock price hit the daily limit. On the 2nd, buying was dominant once again.

Phase 1 trial of anti-transferrin receptor 1 (TfR1) antibody PPMX-T003 has ended.

GLOE<9565> 2183 -54

Temporarily gaining popularity on the 1st after the research institute for broadcasting technology became a subsidiary. On the 2nd, selling was dominant.